RxDoctor Payments Data

Jillian Sullivan, APRN

Adult Health · Farmington, CTNPI 1639423734

Payments from drug & device makers

$2,805in general payments, 2019–2025

Across 141 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$574
  • Novo Nordisk$310
  • Lilly USA, LLC$282
  • Boehringer Ingelheim$208
  • GSK$195
  • AstraZeneca$150
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,805 in reported general payments places this provider in the 80th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,221
Medicare patients
83
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$59,906
FarxigaDapagliflozin Propanediol13$22,222
JardianceEmpagliflozin11$18,392
BelbucaBuprenorphine Hcl13$12,116
Atorvastatin Calcium153$1,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,276
Gabapentin44$1,186
Rosuvastatin Calcium152$1,161
Duloxetine Hcl17$1,141
Ezetimibe37$1,101
Levothyroxine Sodium89$998
Albuterol Sulfate HfaAlbuterol Sulfate37$916
SynthroidLevothyroxine Sodium11$890
ValacyclovirValacyclovir Hcl12$746
Pantoprazole Sodium46$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$310$59,90653 claims
AstraZenecaFarxiga$150$22,22213 claims
Boehringer IngelheimJardiance$208$18,39211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$99889 claims
AbbVieSynthroid$574$89011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 adult health providers in Connecticut.

Other adult health in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →